Hydroxyurea Medac

Hydroxycarbamide, the active ingredient in Hydroxyurea Medac, is an antimetabolite presented as an oral tablet for oral use. It is employed to modify disease processes in several hematologic disorders and certain solid tumors.

GNH USA supplies Hydroxyurea Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across EU and other markets, and ensures timely delivery to meet clinical demand.

Hydroxyurea Medac is used in hematologic disease pathways and certain malignancies to reduce abnormal cell proliferation.

- Sickle cell disease: increases fetal hemoglobin levels, reducing vaso‑occlusive crises. - Chronic myelogenous leukemia: inhibits leukemic cell proliferation. - Polycythemia vera: lowers red blood cell mass and hematocrit. - Essential thrombocythemia: reduces platelet counts and thrombotic risk. - Melanoma: used as part of combination regimens to limit tumor growth.

Hydroxyurea can cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Myelosuppression (anemia, neutropenia, thrombocytopenia) - Gastrointestinal upset (nausea, vomiting, abdominal pain) - Skin changes (hyperpigmentation, rash) - Alopecia (hair loss) - Elevated liver enzymes - Fever or flu‑like symptoms

Serious or Rare Side Effects: - Severe bone marrow failure - Acute renal insufficiency - Pulmonary toxicity (interstitial pneumonitis) - Leg ulcers or severe skin ulceration - Teratogenic effects (birth defects) - Secondary malignancies (e.g., leukemia).

Hydroxyurea requires careful monitoring and patient counseling due to its potent pharmacologic activity.

- Baseline and periodic blood counts: monitor for myelosuppression. - Liver and renal function tests: assess organ tolerance before and during therapy. - Pregnancy risk: contraindicated in pregnancy; discuss contraception. - Breastfeeding: avoid use while nursing. - Drug interactions: review concomitant medications that affect bone marrow. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Hydroxyurea may interact with other agents, altering efficacy or toxicity.

Major Interactions (Avoid): - Concurrent use with other myelosuppressive drugs (e.g., chemotherapy, azathioprine) may exacerbate bone marrow suppression. - Live vaccines: increased risk of infection; avoid during treatment.

Moderate Interactions (Monitor Closely): - Antiretrovirals (e.g., zidovudine): may enhance hematologic toxicity. - NSAIDs: can increase risk of gastrointestinal irritation. - Allopurinol: may affect renal clearance of hydroxyurea. - Phenytoin: may reduce hydroxyurea plasma levels. - Vitamin C supplements: may increase hydroxyurea absorption and toxicity.